“…diabetes (Oyama et al, 1986;Pieper & Gross, 1988;Durante et al, 1988;Tanz et al, 1989;Kamata et al, 1989;Cameron & Cotter, 1992a), but several have found no impairment (White & Carrier, 1986;Wakabayashi et al, 1987;Head et al, 1987;Gebremedhin et al, 1988;Mulhern & Docherty, 1989;Kappagoda et al, 1989). The explanation for these to the untreated diabetic group (pED50 [-log dose discrepant findings is not obvious, but variations in the duras)]: ARI-treated diabetic 9.90 ± 0.13, n = 18, versus tion and severity of diabetes and species differences, could be diabetic 9.87 ± 0.10, n = 20, NS) (Figure 3) on, ARI-treatment had no significant effect on The primary aim of this study was to determine whether line sensitivity in the aortae from diabetic rats the administration of the aldose reductase inhibitor, ponal-RI-treated diabetic 7.40 ± 0.06, versus 7.30 ± 0.06, restat, would prevent the development of endothelial dysr the untreated diabetic, NS) (Figure 4).…”